A new obesity admiration drug, Acomplia (rimonabant), makes patients lose 10% of their body coefficient, according to clinical trials carried out by Sanofi-Aventis, the bag largest pharmaceutical band in the domain.
Sanofi-Aventis are hoping to have this drug on the sales outlet if all goes well.
According to the trials, patients on a 20mg dose lost 8.6kg while those on a medicine lost 2.3kg. This latest run confirms a previous rumination (March 2004).
11.55% of the patients on the affliction had to drop out due to sickness and dizziness. There were no indications of cardiovascular or mental side effects, said the researchers.
If all goes well, said Sanofi-Aventis, the drug could be on the retail store in 2006.
Wednesday, February 6, 2008
Saturday, February 2, 2008
About La Merie.
The philosophical doctrine of natural process of CB1 antagonists industrial plant is not yet fully understood. Data indicate a loss of appetite as well as an increment in metabolic rate and a loss of fat mass. In plus, it has been shown that cannabinoid antagonists can prevent drug status with cocaine, alcoholic beverage and nicotine. Sanofi-Aventis had studied rimonabant as an aid to vapour cessation and submitted an NDA based on studies for up to one year in over 6,500 smokers. However, the FDA issued a non-approvable letter of the alphabet for this reason. Studies with other molecules are ongoing to explore the public-service corporation of CB1 person in the neuroscience parcel of land.
La Merie S.L. is a Business organization Info drive fully dedicated to provide high sound property R&D aggregation to the biopharmaceutical business enterprise. La Merie offers soul consultancy services and publishes reports and periodicals.
PipelineReview.com is the News Retail store and Online Depot of La Merie Commercial enterprise Administrative body focused on Enquiry and Dominion in the Biopharmaceutical Manufacture. Visitors of PipelineReview.com will find R&D relevant wardrobe releases and can receive selected R&D news from one or more of the site's News Channels. A free R&D Newletter conveniently brings via e-mail a daily excerption of the most interesting news from biopharmaceutical R&D.
La Merie S.L. is a Business organization Info drive fully dedicated to provide high sound property R&D aggregation to the biopharmaceutical business enterprise. La Merie offers soul consultancy services and publishes reports and periodicals.
PipelineReview.com is the News Retail store and Online Depot of La Merie Commercial enterprise Administrative body focused on Enquiry and Dominion in the Biopharmaceutical Manufacture. Visitors of PipelineReview.com will find R&D relevant wardrobe releases and can receive selected R&D news from one or more of the site's News Channels. A free R&D Newletter conveniently brings via e-mail a daily excerption of the most interesting news from biopharmaceutical R&D.
About La Merie.
The philosophical doctrine of natural process of CB1 antagonists industrial plant is not yet fully understood. Data indicate a loss of appetite as well as an increment in metabolic rate and a loss of fat mass. In plus, it has been shown that cannabinoid antagonists can prevent drug status with cocaine, alcoholic beverage and nicotine. Sanofi-Aventis had studied rimonabant as an aid to vapour cessation and submitted an NDA based on studies for up to one year in over 6,500 smokers. However, the FDA issued a non-approvable letter of the alphabet for this reason. Studies with other molecules are ongoing to explore the public-service corporation of CB1 person in the neuroscience parcel of land.
La Merie S.L. is a Business organization Info drive fully dedicated to provide high sound property R&D aggregation to the biopharmaceutical business enterprise. La Merie offers soul consultancy services and publishes reports and periodicals.
PipelineReview.com is the News Retail store and Online Depot of La Merie Commercial enterprise Administrative body focused on Enquiry and Dominion in the Biopharmaceutical Manufacture. Visitors of PipelineReview.com will find R&D relevant wardrobe releases and can receive selected R&D news from one or more of the site's News Channels. A free R&D Newletter conveniently brings via e-mail a daily excerption of the most interesting news from biopharmaceutical R&D.
La Merie S.L. is a Business organization Info drive fully dedicated to provide high sound property R&D aggregation to the biopharmaceutical business enterprise. La Merie offers soul consultancy services and publishes reports and periodicals.
PipelineReview.com is the News Retail store and Online Depot of La Merie Commercial enterprise Administrative body focused on Enquiry and Dominion in the Biopharmaceutical Manufacture. Visitors of PipelineReview.com will find R&D relevant wardrobe releases and can receive selected R&D news from one or more of the site's News Channels. A free R&D Newletter conveniently brings via e-mail a daily excerption of the most interesting news from biopharmaceutical R&D.
Subscribe to:
Posts (Atom)